See What HealthDay Can Do For You
Contact Us

Aspirin Modestly Reduces Risk of Preeclampsia

Also reduces risk of premature delivery and adverse pregnancy outcomes

THURSDAY, May 17 (HealthDay News) -- Aspirin modestly reduces the risk of preeclampsia, premature delivery and serious adverse pregnancy outcomes in at-risk women, according to a meta-analysis published online May 17 in The Lancet.

Lisa M. Askie, Ph.D., from the University of Sydney in Australia, and colleagues performed a meta-analysis of 31 randomized clinical trials of anti-platelet agents to prevent preeclampsia. The trials involved 32,217 women and 32,819 infants, and 98 percent of women were in trials of 50 mg to 150 mg aspirin alone per day.

The researchers found that women receiving anti-platelet agents had a reduced risk of preeclampsia (relative risk, 0.90), a reduced risk of delivering before 34 weeks (RR, 0.90), and a reduced risk of having a serious adverse outcome (RR, 0.90). Anti-platelet agents did not significantly affect the risk of death in fetus or infant, having a small-for-gestational-age infant, or bleeding in the women or their infants.

"There are certain settings in which preeclampsia is almost a certainty, including women with preeclampsia in more than one pregnancy or women with chronic hypertension and preeclampsia in a previous pregnancy," James M. Roberts, M.D., and Janet M. Catov, Ph.D., of the University of Pittsburgh, write in an accompanying editorial. "In these settings, aspirin is justified."

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.